OneSource Specialty Pharma Limited has achieved a significant regulatory milestone with the Saudi Food and Drug Authority (SFDA) approval of its generic Ozempic (semaglutide) for the Saudi Arabian market. The approval enables the company to commercialise the diabetes therapy through an exclusive partnership with Hikma Pharmaceuticals PLC across the Middle East and North Africa (MENA) region.

Strategic Partnership Details

The exclusive agreement establishes a clear division of responsibilities between the two pharmaceutical companies:

Market Significance

The approval represents OneSource's strategic entry into Saudi Arabia, identified as one of the largest markets globally for GLP-1 therapies. The partnership positions both companies to capitalise on the rising demand for semaglutide while expanding access to affordable generic alternatives across the region.

Mr. Neeraj Sharma, CEO & MD of OneSource Specialty Pharma Limited, expressed enthusiasm about the development: "We are extremely excited to secure SFDA approval for semaglutide in Saudi Arabia, one of the largest GLP-1 market globally with significant long-term potential. We are confident that collaborating with Hikma, the largest pharmaceutical company in the MENA region by sales, will give us a strong platform to scale access to this important therapy across both private and institutional customers."

Company Capabilities

OneSource operates as a pure-play specialty pharmaceutical CDMO with comprehensive manufacturing capabilities:

Partnership Leverage

Hikma Pharmaceuticals brings substantial commercial expertise to the partnership, operating as the largest pharmaceutical company in MENA based on sales. The company maintains extensive commercial reach and institutional relationships across the region, providing the infrastructure necessary to scale access to semaglutide therapy.

The collaboration combines OneSource's manufacturing capabilities with Hikma's established market presence, creating a comprehensive approach to generic semaglutide distribution in the MENA region. This strategic alignment supports both companies' shared objective of increasing patient access to high-quality, affordable generic alternatives.

Source:

Onesource Specialty Pharma Limited has received a regulatory disclosure from Pronomz Ventures LLP regarding the acquisition of additional equity shares. The disclosure, made under Regulation 29(2) of SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011, details a strategic increase in shareholding by the promoter group entity.

Transaction Details

Pronomz Ventures LLP acquired 33,906 equity shares of Onesource Specialty Pharma Limited through open market purchases on January 30, 2026. The acquisition represents 0.03% of the company's total share capital.

Shareholding Pattern Changes

The acquisition resulted in a marginal increase in the promoter group's collective shareholding. Before the transaction, Pronomz Ventures LLP and its persons acting in concert held 3,45,71,199 shares, representing 30.17% of the total voting capital.

Promoter Group Structure

The disclosure identifies Pronomz Ventures LLP as the acquirer, with several entities and individuals classified as persons acting in concert. The group includes:

• Karuna Business Solutions LLP
• Tenshi Pharmaceuticals Private Limited
• Arco Lab Private Limited
• Arun Kumar Pillai
• Vineetha Mohanakumar Pillai
• Padmakumar Karunakaran Pillai
• Sajitha Pillai
• Rajitha Gopalakrishnan
• Aditya Arun Kumar
• Hemalatha Pillai

Company Capital Structure

Onesource Specialty Pharma Limited maintains a stable equity share capital structure. The company's total equity share capital remains unchanged at 11,46,21,201 equity shares of Rs. 1 each, fully paid up. The shares are listed on both BSE Limited (Scrip Code: 544292) and National Stock Exchange of India Limited (Scrip Code: ONESOURCE).

Regulatory Compliance

The disclosure was signed by Jyothinarayasha Sriraman Ramaprasad, Designated Partner of Pronomz Ventures LLP (DIN: 00173696), on February 02, 2026. The filing ensures compliance with SEBI regulations governing substantial acquisitions and maintains transparency in shareholding changes for publicly listed companies.